Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Real Time Quote from BATS)

$111.00 USD

111.00
464,163

+1.54 (1.41%)

Updated Apr 29, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study

by Zacks Equity Research

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View

by Zacks Equity Research

Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.

Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -7.28% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises

by Zacks Equity Research

Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.

Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 0% and 23.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Avalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 12.37% and 52.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.

Jazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales

by Zacks Equity Research

Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.

Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Jazz (JAZZ) Could Beat Earnings Estimates Again

by Zacks Equity Research

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Invesco S&P MidCap 400 Equal Weight ETF (EWMC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EWMC

Should Invesco S&P MidCap 400 Equal Weight ETF (EWMC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for EWMC

Can Zymeworks (ZYME) Beat Expectations This Earnings Season?

by Zacks Equity Research

In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.